会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明申请
    • PROCESS FOR PREPARING BICYCLIC COMPOUNDS
    • 制备双相化合物的方法
    • WO2006108689A2
    • 2006-10-19
    • PCT/EP2006/003480
    • 2006-04-06
    • SB PHARMCO PUERTO RICO INCNEUROCRINE BIOSCIENCES INCANDREOTTI, DanieleBACCHI, SergioDELPOGETTO, MonicaGUELFI, SimonePERBONI, AlcideRIBECAI, AriannaSPADA, SimoneSTABILE, PaoloTAMPIERI, Marsia
    • ANDREOTTI, DanieleBACCHI, SergioDELPOGETTO, MonicaGUELFI, SimonePERBONI, AlcideRIBECAI, AriannaSPADA, SimoneSTABILE, PaoloTAMPIERI, Marsia
    • C07D471/04A61K31/437A61P1/00A61P25/00
    • C07D471/04C07D207/22
    • The present invention relates to a novel process for preparing compounds of formula (IA), which are potent and specific antagonists of corticotropin-releasing factor (CRF) receptors, from intermediate compounds of formula (I), by a coupling reaction catalysed by copper (I) (Ia)wherein R is aryl or heteroaryl, each of which may be substituted by 1 to 4 groups selected from: halogen, C1-C6 alkyl, C1-C6 alkoxy, halo C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halo C1-C6 alkoxy, C(O)R 5 , nitro, -NR 6 R 7 , cyano, and a group R 8 ; R 1 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halo C1-C6 alkyl, halo C1-C6 alkoxy, halogen, NR 6 R 7 or cyano; R 5 is a C1-C4 alkyl, -OR 6 or -NR 6 R 7 ; R 6 is hydrogen or C1-C6 alkyl; R 7 is hydrogen or C1-C6 alkyl; R 8 is a 5-6 membered heterocycle, which may be saturated or may contain one to three double bonds, and which may be substituted by 1 or more R 11 groups; R 9 is a C1-C6 alkyl that may be substituted by one or more groups selected from: C3-C7 cycloalkyl, C1-C6 alkoxy, haloC1-C6 alkoxy, hydroxy, haloC1-C6 alkyl; R11 is C3-C7 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy, halo C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halo C1-C6 alkoxy, hydroxy, halogen, nitro, cyano, or C(O)NR 6 R 7 ; X is halogen; and R'' corresponds to R; R'' 1 corresponds to R 1 ; R 2 is hydrogen, C3-C7 cycloalkyl, or a group R 9 ; R 3 is C3-C7 cycloalkyl, or a group R 9 ; or R 2 and R 3 together with N form a 5-14 membered heterocycle, which may be substituted by 1 to 3 R 10 groups; R'' 4 is hydrogen; R'' 5 corresponds to R 5 ; R'' 6 corresponds to R 6 ; R'' 7 corresponds to R 7 ; R'' 8 corresponds to R 8 ; R'' 9 corresponds to R 9 ; R 10 is a group R 8 , C3-C7 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy, halo C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halo C1-C6 alkoxy, hydroxy, halogen, nitro, cyano, C(O)NR 6 R 7 , phenyl which may be substituted by 1 to 4 R 11 groups; R'' 11 corresponds to R 11 .
    • 本发明涉及由式(I)的中间体化合物通过铜催化的偶联反应制备式(IA)化合物的新方法,其为促肾上腺皮质激素释放因子(CRF)受体的有效和特异性拮抗剂 I)(Ia)其中R是芳基或杂芳基,其各自可以被1至4个选自以下的基团取代:卤素,C 1 -C 6烷基,C 1 -C 6烷氧基,卤代C 1 -C 6烷基,C 2 -C 6烯基,C 2 -C 6炔基,卤代C 1 -C 6烷氧基,C(O)R 5,硝基,-NR 6 R 7,氰基和 基团R 8; R 1是氢,C 1 -C 6烷基,C 2 -C 6烯基,C 2 -C 6炔基,卤代C 1 -C 6烷基,卤代C 1 -C 6烷氧基,卤素,NR 6 R 7或氰基; R 5是C 1 -C 4烷基,-OR 6或-NR 6 R 7; R 6是氢或C 1 -C 6烷基; R 7是氢或C 1 -C 6烷基; R 8是5-6元杂环,其可以是饱和的或可以含有一至三个双键,并且其可以被1个或更多个R 11个基团取代; R 9是可以被一个或多个选自以下的基团取代的C 1 -C 6烷基:C 3 -C 7环烷基,C 1 -C 6烷氧基,卤代C 1 -C 6烷氧基,羟基,卤代C 1 -C 6烷基; R 11是C 3 -C 7环烷基,C 1 -C 6烷基,C 1 -C 6烷氧基,卤代C 1 -C 6烷基,C 2 -C 6烯基,C 2 -C 6炔基,卤代C 1 -C 6烷氧基,羟基,卤素,硝基,氰基或C( O)NR 6 - [R 7 ; X是卤素; 并且R“对应于R; R“1 对应于R 1; R 2是氢,C 3 -C 7环烷基或基团R 9; R 3是C 3 -C 7环烷基或基团R 9; 或R 2和R 3与N一起形成5-14元杂环,其可以被1至3个R 10个基团取代; R“4是氢; R“5”对应于R 5; R“6”对应于R 6; R“7对应于R 7; R“8对应于R 8; R“9对应于R 9; R 10是基团R 8,C 3 -C 7环烷基,C 1 -C 6烷基,C 1 -C 6烷氧基,卤代C 1 -C 6烷基,C 2 -C 6链烯基, C 6炔基,卤代C 1 -C 6烷氧基,羟基,卤素,硝基,氰基,C(O)NR 6 R 7,可被1至4个R 11个组; R“”11“对应于R 11。